These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26312961)

  • 1. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
    Broglio K; Pergolizzi J; Kowalski M; Lynch SY; He E; Wen W
    Pain Pract; 2017 Mar; 17(3):382-391. PubMed ID: 27317188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
    Taber L; Baldridge S; He E; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):133-139. PubMed ID: 27983881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.
    Kapil RP; Cipriano A; Wen W; Yu Lynch S; He E; Colucci SV; Harris SC
    Clin Ther; 2016 Feb; 38(2):302-14. PubMed ID: 26749219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate.
    Argoff C; Arnstein P; Stanos S; Robinson CY; Galer BS; Gould E; Gammaitoni A
    J Opioid Manag; 2015; 11(5):417-24. PubMed ID: 26535969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain.
    Pergolizzi J; Kowalski M; He E
    Pain Med; 2018 May; 19(5):967-977. PubMed ID: 28371835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
    Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
    Pain Med; 2016 May; 17(5):820-31. PubMed ID: 26814240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets.
    Bartoli A; Michna E; He E; Wen W
    J Opioid Manag; 2015; 11(6):519-33. PubMed ID: 26728649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of once-daily Hysingla extended-release tablets in patients with baseline depression or anxiety.
    Taber L; He E; Ripa SR
    Pain Manag; 2017 Nov; 7(6):473-488. PubMed ID: 28747087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
    Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
    Pain Med; 2017 Jul; 18(7):1278-1291. PubMed ID: 27651514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.